ABOUT US
An Industry Leader
Founded in 2011, Diabest is a privately held company, developing a dietary supplement to support blood glucose levels, based on Sarcopoterium Spinosum extract, to treat metabolic diseases. While sharply focused on type 2 diabetes, the technology could potentially treat a wide range of metabolic disorders.
Our treatment integrates proprietary botanical extract method and optimized growing protocol of S. spinosum to maintain healthy blood sugar levels and to evade diabetic complications.
TOVIT ROSENZWEIG
Dr. Tovit Rosenzweig is a Head of Laboratory for Metabolism Research in Ariel University Center. The main research focus of Dr. Rosenzweig is on the study of diabetes, mainly type 2, as well as on several other aspects of the metabolic syndrome, including obesity and fatty liver. The research is mostly centered on the potential beneficial effects of herbs and nutraceuticals on these disorders.
YITSHAK “ITSIK” FRANCIS
Dr. Yitshak Francis is director of business development at Ariel Scientific Innovations, Ariel University’s technology transfer company. Dr. Francis received his biology degree from the Technion in Israel and his Ph.D. in medical molecular biology from University College, London. He conducted his postdoctoral training at Columbia University, where he worked on several drug development projects. He was a co-founder and CEO for Citta Pharmaceuticals, a Columbia biotechnology spin-off that develops Alzheimer’s therapies
OUR PARTNERSHIP WITH ARIEL UNIVERSITY
The Diabest team collaborates closely with Ariel University to develop and commercialize our products. Diabest has an exclusive license agreement with Ariel University to commercialize these technologies.